Abstract
Objectives
The generic reference price (GRP) was introduced in Italy in 2001. The main purpose of this paper is: (a) producing evidence regarding the effect of GRP on prices; (b) testing the hypothesis that there is a reallocation of demand from the genericated (and reference-priced) molecules to patent-protected products that have the same therapeutic indication.
Methods
The analysis used a unique dataset of quantities and revenues of six therapeutic groups that were observed for more than a decade. Difference-in-differences analysis is applied. Prices are adjusted for all the regulatory interventions in the ten years of observations, to control for confounding impact of these interventions.
Results
On average, prices dropped 13 % more in groups to which GRP was applied than in other groups. Moreover, each entry of a new generic was associated with a price drop of around 2.8 %. On the other hand, GRP did not induce any significant switching towards in-patent molecules.
Conclusions
We provide the first empirical results of the impact of GRP on prices in Italy and evidence that GRP cannot be held solely responsible for the often reported demand reallocation towards new and in-patent molecules.
Similar content being viewed by others
References
OECD: OECD Health Data 2012. http://stats.oecd.org/Index.aspx?DataSetCode=SHA (2012). Accessed 6 Feb 2012
Fattore, G., Jommi, C.: The last decade of Italian pharmaceutical policy: instability or consolidation? Pharmacoeconomics 26, 5–15 (2008)
Jommi, C., Armeni, P., De Luca, C., et al.: Il governo regionale dell’assistenza farmaceutica e il suo impatto sulla spesa. In: Cantù, E. (ed.) Rapporto OASI 2011, L’aziendalizzazione della sanità italiana, pp. 259–296. Egea, Milano (2011)
Mapelli, V., Lucioni, C.: Spending on pharmaceuticals in Italy: macro constraints with local autonomy. Value Health 6(Suppl. 1), S31–S45 (2003)
Ghislandi, S., Krulichova, I., Garattini, L.: Pharmaceutical policy in Italy: towards a structural change? Health Policy 72, 53–73 (2005)
Garattini, L., Ghislandi, S.: Off-patent drugs in Italy: a short-sighted view? Eur. J. Health Econ. 7, 79–83 (2006)
Danzon, P., Liu, H.: Reference Pricing and Physician Drug Budgets: The German Experience in Controlling Pharmaceutical Expenditures. Working Paper. The Wharton School, Philadelphia (1997)
Brekke, K.R., Koningbauer, I., Straune, O.R.: Reference pricing for pharmaceuticals. J. Health Econ. 26, 613–642 (2007)
Brekke, K.R., Holmas, T.H., Straume, O.R.: Reference pricing, competition, and pharmaceutical expenditures: theory and evidence from a natural experiment. J. Pub. Econ. 95, 626–638 (2011)
Miraldo, M.: Reference pricing and firms’ pricing strategies. J. Health Econ. 28, 176–197 (2009)
Ghislandi, S.: Competition and the reference pricing scheme for pharmaceuticals. J. Health Econ. 30, 1137–1149 (2011)
Galizzi, M., Ghislandi, S., Miraldo, M.: Effects of reference pricing in pharmaceutical markets: a review. Pharmacoeconomics 29, 17–33 (2011)
Puig-Junoy, J.: Incentives and pharmaceutical reimbursement reforms in Spain. Health Policy 67, 149–165 (2005)
Augurzky, B., Göhlmann, S., Greß, S., et al.: Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach. Health Econ. 18, 421–436 (2009)
Simoens, S., De Bruyn, K., Bogaert, M.: Pharmaceutical policy regarding generic drugs in Belgium. Pharmacoeconomics 23, 755–766 (2005)
Stargardt, T.: The impact of reference pricing on switching behaviour and health care utilization: the case of statins in Germany. Eur. J. Health Econ. 11, 267–277 (2010)
The World Health Organization (WHO) Collaborating Centre for Drugs Statistics Methodology: ATC/DDD Index 2009. http://www.whocc.no/atc_ddd_index (2009). Accessed 30 Nov 2009
AIFA (Agenzia Italiana del Farmaco): L’uso dei farmaci in Italia: rapporto nazionale, Anno 2009, Rapporto OSMED. Il Pensiero Scientifico Ed, Roma (2010)
Pavcnik, N.: Do pharmaceutical prices respond to potential patient out-of-pocket expenses? Rand. J. Econ. 33, 46–92 (2002)
Grootendorst, P., Marshall, J., Holbrook, A., et al.: The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs. Health Serv. Res. 40, 1297–1317 (2005)
Bertrand, M., Duflo, E., Sendhil, M.: How much should we trust differences-in-differences estimates? Q. J. Econ. 119, 249–275 (2004)
Lee, M.: Micro-Econometrics for Policy. Programs and Treatment Effects. Oxford University Press, Oxford (2005)
Acknowledgments
This research has been carried out thanks to an unconditional grant from Menarini srl. Menarini also provided the authors with market data (IMS Health).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ghislandi, S., Armeni, P. & Jommi, C. The impact of generic reference pricing in Italy, a decade on. Eur J Health Econ 14, 959–969 (2013). https://doi.org/10.1007/s10198-012-0442-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10198-012-0442-3